Petal Surgical Secures New Funding for Incisionless Surgical Robot

Funding for Incisionless Surgical Robot">

['Petal Surgical today announced a new financing round to support its incisionless surgery platform as it works toward first-in-human studies. The company, which emerged from stealth with a $10 million Series A last fall, has now secured additional funding to fuel its innovative approach to surgery.', "The latest financing round was led by Blue Pool Capital, with participation from Salience Capital, A&E Investments, TIME Ventures, and existing investors, including Actions Capital (formerly K50 Ventures). This brings Petal Surgical's total funding to over $25 million, following a $10 million Series A and another financing round in March that eclipsed $25 million.

Notably, Intuitive co-founder Dr. Fred Moll, considered the 'father of surgical robotics,' joined Petal Surgical's board in March and participated in the October financing round.", "Petal Surgical's platform uses acoustic liquefaction, a form of histotripsy, AI, and robotics to provide precise, reproducible tissue treatment. The company's technology utilizes Millisecond Pulse Histotripsy and integrates robotics, imaging, and AI-driven controls.

Petal Surgical plans to use its latest funds to accelerate R&D, expand clinical readiness activities, and support its path toward human trials. The company believes its incisionless surgery method could create a new standard of care, making advanced treatments safer, more accessible, and less traumatic for patients worldwide.", "The company's approach aims to eliminate cutting, pain, trauma, and other typical surgical risks, allowing the body to heal naturally with no cuts, burns, or toxicity. Histotripsy, a method that uses focused ultrasound waves to destroy tumors and other abnormal tissue, is also being developed by HistoSonics.

Petal Surgical's platform works with the body's natural abilities to heal by creating vapor-filled cavities one at a time, allowing for clear and connected treatment regions with more opportunities to break down tougher tissues.", "Investors are optimistic about Petal Surgical's potential. 'We invest in innovative market leaders who have bigger ambitions than incremental change,' said Christopher Wu, chief investment officer at Blue Pool Capital. 'In Petal we see a big opportunity to change and improve healthcare, beginning with incisionless surgery.' Lip-Bu Tan, CEO of Intel and Petal Surgical investor, added, 'Petal is a unique mission that is solving hard problems in biophysics using physical AI.

We are excited about its potential to completely redefine our expectations of surgical outcomes.'", 'Petal Surgical was founded by image-guided surgery engineer Prash Chopra, neurosurgeon Dr. Bowen Jiang, robotic-assisted spine surgery pioneer Dr. Nicholas Theodore, and Rony Abovitz, a founder of Mako Surgical, which is now owned by Stryker.']